Thursday, October 16, 2025 10/16/2025

Engineering Dual-Targeted Nanoplatforms to Effectively Treat NSCLC.

Award Number: R01EB032869
ORGANIZATION: NATIONAL INSTITUTE Of BIOMEDICAL IMAGING & BIOENGINEERING
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/30/2022
PERIOD OF PERFORMANCE END DATE: 05/31/2026

Group Awards By:

View Award Description

Engineering Dual-Targeted Nanoplatforms to Effectively Treat NSCLC. - ABSTRACT Nanomedicine provides new opportunities to solve medical problems that were previously perceived as unsolvable by clinicians. One such problem is drug resistance in Non-Small Cell Lung Cancer (NSCLC). Attempts to overcome the resistance using small molecule inhibitors have failed to restore the drug sensitivity. Alternative compensation survival pathways emerge to allow the regrowth of the tumor. To abate the tumor growth, we need to suppress more than one survival pathway with minimal or no side effects. Nanoparticles possess the ability to selectively and simultaneously arrest multiple survival pathways to control the growth of the tumor. However, nanoparticles to co-knockdown multiple cross-linked survival pathways have not been explored yet. We recently identified two targets AXL and FN14 and demonstrated that the cross-talk between these markers is responsible for resistance in EGFR mutant NSCLC. Subsequently, we designed nanoparticles to simultaneously co-knockdown both AXL and FN14 in the tumor, disrupted the cross-talk, and successfully overcame drug resistance in murine models. The logical next step is to validate the findings in clinically relevant animal models and patient samples. It is equally important to optimize the size of nanoparticles further to maximize deep tumor delivery with favorable in vivo characteristics. Therefore, in this proposal, we will synthesize different sizes of NP, understand their ability to penetrate deep inside the tumor to fully restore drug sensitivity for a long-lasting therapeutic response. We will use patient tissues, patient-derived organoids, drug- resistant cell lines, orthotopic animal models, and patient-derived xenografts to establish the efficacy of the nanoplatform. The data will validate our new nanoparticle platform, as a promising strategy to combat drug resistance in NSCLC and catalyze clinical trials in the future.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $629,729 )
2025	2025	UNIVERSITY OF MISSOURI SYSTEM	121 UNIVERSITY HALL	COLUMBIA	MO	65211	BOONE	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	000	4	5/1/2025	NON-COMPETING CONTINUATION	$629,729
														Subtotal = $629,729

Issue Date FY: 2024 ( Subtotal = $634,874 )
2024	2024	UNIVERSITY OF MISSOURI SYSTEM	121 UNIVERSITY HALL	COLUMBIA	MO	65211	BOONE	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	000	3	6/14/2024	NON-COMPETING CONTINUATION	$634,874
														Subtotal = $634,874

Issue Date FY: 2023 ( Subtotal = $661,001 )
2023	2023	UNIVERSITY OF MISSOURI SYSTEM	121 UNIVERSITY HALL	COLUMBIA	MO	65211	BOONE	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	000	2	7/18/2023	NON-COMPETING CONTINUATION	$661,001
														Subtotal = $661,001

Issue Date FY: 2022 ( Subtotal = $687,752 )
2022	2022	UNIVERSITY OF MISSOURI SYSTEM	316 UNIVERSITY HALL	COLUMBIA	MO	65211	BOONE	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	000	1	9/16/2022	NEW	$687,752
														Subtotal = $687,752

Grand Total All Awards = $2,613,356

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Engineering Dual-Targeted Nanoplatforms to Effectively Treat NSCLC.

Award Number: R01EB032869

ORGANIZATION: NATIONAL INSTITUTE Of BIOMEDICAL IMAGING & BIOENGINEERING

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/30/2022

PERIOD OF PERFORMANCE END DATE: 05/31/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer